Risks connected with the use of conventional and genetically engineered vaccines
- PMID: 1413441
- DOI: 10.1080/01652176.1992.9694344
Risks connected with the use of conventional and genetically engineered vaccines
Abstract
A review is given of real and potential risks connected with the use of conventional and genetically engineered live and dead vaccines. Special attention is given to live carrier vaccines expressing one or more heterologous genes of other microorganisms. Because most carrier vaccines are still in an experimental phase, there is only limited experience with the risks of carrier vaccines. There are three potential risks of live carrier vaccines which will be discussed: 1. Changes in cell, tissue, of host tropism, and virulence of the carrier through the incorporation of foreign genes. 2. Exchange of genetic information with other vaccine or wild-type strains of the carrier organism. 3. Spread in the environment. Only limited experimental data are available on changes in biological behaviour of microorganisms through the incorporation of foreign genes. For example, there are indications that vaccinia virus carrying the attachment protein G of respiratory syncytial virus (RSV) replicates better in lungs of mice than vaccinia virus carrying other genes of RSV. Poxviruses carry genes that probably determine their replication in different hosts. Exchange of such host tropism genes might alter their host spectrum. Recombination between herpesvirus vaccine or wild-type strains may lead to the appearance of virulent strains with of without heterologous genes. Before carrier vaccines are applied, these risks must be thoroughly evaluated case-by-case. Potential methods for the design of safe carrier vaccines are discussed.
Similar articles
-
Biological safety concepts of genetically modified live bacterial vaccines.Vaccine. 2007 Jul 26;25(30):5598-605. doi: 10.1016/j.vaccine.2006.11.058. Epub 2006 Dec 5. Vaccine. 2007. PMID: 17239999 Review.
-
Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.J Virol. 2015 Oct;89(20):10319-32. doi: 10.1128/JVI.01380-15. Epub 2015 Jul 29. J Virol. 2015. PMID: 26223633 Free PMC article.
-
Protective and disease-enhancing immune responses to respiratory syncytial virus.J Infect Dis. 1995 Jan;171(1):1-7. doi: 10.1093/infdis/171.1.1. J Infect Dis. 1995. PMID: 7798649
-
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.J Infect Dis. 2005 Apr 1;191(7):1093-104. doi: 10.1086/427813. Epub 2005 Mar 1. J Infect Dis. 2005. PMID: 15747245 Clinical Trial.
-
Preclinical safety assessment considerations in vaccine development.Pharm Biotechnol. 1995;6:61-79. doi: 10.1007/978-1-4615-1823-5_3. Pharm Biotechnol. 1995. PMID: 7551238 Review. No abstract available.
Cited by
-
Smallpox: gone but not forgotten.Infection. 1998 Sep-Oct;26(5):263-9. doi: 10.1007/BF02962244. Infection. 1998. PMID: 9795781 Review.
-
Preliminary Work Towards Finding Proteins as Potential Vaccine Candidates for Vibrio cholerae Pakistani Isolates through Reverse Vaccinology.Medicina (Kaunas). 2019 May 23;55(5):195. doi: 10.3390/medicina55050195. Medicina (Kaunas). 2019. PMID: 31126058 Free PMC article.
-
Jenner-predict server: prediction of protein vaccine candidates (PVCs) in bacteria based on host-pathogen interactions.BMC Bioinformatics. 2013 Jul 1;14:211. doi: 10.1186/1471-2105-14-211. BMC Bioinformatics. 2013. PMID: 23815072 Free PMC article.
-
VacSol: a high throughput in silico pipeline to predict potential therapeutic targets in prokaryotic pathogens using subtractive reverse vaccinology.BMC Bioinformatics. 2017 Feb 13;18(1):106. doi: 10.1186/s12859-017-1540-0. BMC Bioinformatics. 2017. PMID: 28193166 Free PMC article.
-
Genetic recombination of pseudorabies virus: evidence that homologous recombination between insert sequences is less frequent than between autologous sequences.Arch Virol. 1995;140(4):671-85. doi: 10.1007/BF01309957. Arch Virol. 1995. PMID: 7794111
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical